FOSUN PHARMA

Fosun Pharma’s 1.3 million‑share buyback boosts shareholder value while its 2026 interim report highlights strong R&D, revenue growth, and disciplined capital allocation.

Fosun Pharmaceutical’s 2026 H1 report shows a sharp earnings jump and strong cash flow, hinting at a valuation rebound driven by strategic BD and biotech innovation.